Refining the toxicity profile of crizotinib

Journal of Thoracic Oncology

Volumn 9, Issue 11, 2014, Pages 1596-1597

  Solomon, Benjamin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CRIZOTINIB; IOTALAMIC ACID; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG RECHALLENGE; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; NEPHROTOXICITY; PRIORITY JOURNAL; SIDE EFFECT; DRUG EFFECTS; KIDNEY; LUNG NEOPLASMS;

HUMANS; KIDNEY; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES;

EID: 84925824590     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000375     Document Type: Editorial

References (16)

1. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-1019.
2. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
3. Ou Sh, Bang TJ, Camidge DR, et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). J Clin Oncol 2013; 31(Suppl; abstr 8032.
4. Camidge DR, Ou SHI, Shapiro GI, et al. in J Clin Oncol 2014; 32(suppl; abstr 8001):5s.
5. United States Xalkori Package insert. Available at: www.fda.gov/drugs. Accessed September 8, 2014.
6. Kim DK, Shn MJ, Yang P, et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) Ann Oncol 2012; 23.
7. Ou SH, Tong WP, Azada M, Siwak-Tapp C, Dy J, Stiber JA. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer 2013;119:1969-1975.
8. Brosnan EM, Weickhardt AJ, Lu X, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive nonsmall cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 2014;120:664-674.
9. Gastaud L, Ambrosetti D, Otto J, et al. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma. Lung Cancer 2013;82:362-364.
10. Martín Martorell P, Huerta Alvaro M, Solís Salguero MA, Insa Molla A. Crizotinib and renal insufficiency: a case report and review of the literature. Lung Cancer 2014;84:310-313.
11. Camidge DR, Brosnan EM, DeSilva C, Koo PJ, Chonchol M. Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate. J Thorac Oncol 2014;9:1634-1637.
12. Lin Y-T, Wang Y-F, Yang JC-H, et al. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol 2014;9:1720-1725.
13. Warren KS, McFarlane J. The Bosniak classification of renal cystic masses. BJU Int 2005;95:939-942.
14. Klempner SJ, Aubin G, Dash A, Ou SH. Spontaneous regression of crizo-tinib- associated complex renal cysts during continuous crizotinib treatment. Oncologist 2014;19:1008-1010.
15. Awad MM, Lax TP, Slawski BR, Shaw AT. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. J Thorac Oncol 2014;9:1726-1728.
16. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574-580.